{"id":"W2094345654","doi":"10.2337/dc13-0327","title":"Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":150,"is_retracted":false,"has_abstract":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Medicine; Monoclonal antibody; Diabetes mellitus; Type 2 diabetes; Randomized controlled trial; Monoclonal; Antibody; Internal medicine; Immunology; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003019605,0.001096322,0.002314349,0.000234557,0.0003043117,0.0007431354,0.000722428,0.001063712,0.003117365],"category_scores_gemma":[0.001646033,0.0004419511,0.00155519,0.0003407311,0.0006403804,0.0005129926,0.0002550363,0.00212689,0.0004317286],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005762354,"about_ca_system_score_gemma":0.0009333054,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006403185,"about_ca_topic_score_gemma":0.001377765,"domain_scores_codex":[0.999331,0.0004181063,0.00003618177,0.0000764364,0.00006732802,0.00007098356],"domain_scores_gemma":[0.9989293,0.0002917875,0.0002775992,0.00008451952,0.00006780979,0.0003490658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9628552,0.005134803,0.002702018,0.0005482754,0.001404213,0.00005763106,0.00002971922,0.000349845,0.006114074,0.00007764334,0.001129838,0.0195968],"study_design_scores_gemma":[0.9515606,0.03965954,0.006611791,0.00002953712,0.0006793136,0.00005865011,0.000007321848,0.0002782245,0.0005096847,0.00005524542,0.0005400621,0.00001001017],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.982287,0.01128601,0.0009067301,0.000742254,0.0003394163,0.001641491,0.001400631,0.00008412793,0.001312356],"genre_scores_gemma":[0.982113,0.006419182,0.002360288,0.001350983,0.0005479296,0.002752485,0.002175894,0.0000418833,0.002238421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003117365,"threshold_uncertainty_score":0.0159694,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008577696229338936,"score_gpt":0.2799730497491972,"score_spread":0.2713953535198583,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}